Allume from Quintiles Helps Biopharma Navigate Market Entry
RESEARCH TRIANGLE PARK, NC – July 10, 2012 – Quintiles today introduced Allume™, a comprehensive go-to-market service to help biopharmaceutical companies efficiently launch new products and shorten timelines to peak sales, while retaining strategic and corporate control of their assets. Allume™ simplifies and organizes the complex and resource-intensive launch planning process; provides unique data-driven insights from 15 years of market entry experience across the globe; and taps Quintiles’ local market and therapeutic category expertise.
“Biopharma companies are looking for new ways to optimize product value, expedite market access, mitigate commercialization risk, yet retain asset value, while reaching patients across diverse geographic regions,” said Dean Summerfield, Vice President, Consulting, Quintiles. “To maximize value, they need to start planning product launch early in the drug development process, especially when preparing to enter new geographic markets. Through Allume™ Quintiles provides the strategic thinking, local market knowledge, deep therapeutic insight and market access approaches to help our customers map and navigate a pathway to commercial success.”
A unique combination of Consulting, Clinical and Commercial expertise, paired with state-of-the-art software, Allume™ incorporates Quintiles’ years of biopharma product launch experience into flexible, seamless support that complements in-house capabilities. It can be fully customized to each company and product to help identify key market challenges, fast-track launch rollout and improve efficiency in resource management. This cost-effective solution allows companies to benefit from Quintiles’ product lifecycle expertise rather than assume the financial risk of creating their own infrastructure to support launch planning early in the commercialization process.
“Allume™ coordinates decision making around the late phases of development as well as the launch of an asset,” said Dr. Michael Ackermann, Senior Vice President, Global Commercial Solutions at Quintiles. “It is a well-structured and interactive way of accessing the expertise customers need without surrendering strategic control of their asset.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
